Chris has consistently delivered novel therapies to those suffering from serious conditions in both specialty care and rare disease. Through experience in US and Global commercial leadership roles at J&J, Takeda, Acorda, UCB, and now Alexion, Chris has a distinct perspective on critical...
Read More →